Skin & Hair · Skin & Hair peptide (research)
AHK-Cu
- Drug class
- Skin & Hair peptide (research)
- Status
- Compounded (503A)
- Also known as
- ahk copper, ahk peptide, alanyl-histidyl-lysine, ahk cu
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What AHK-Cu is studied for
- Hair follicle support (research)
- Scalp microcirculation (research)
- Anagen phase research (research)
Mechanism of action
AHK-Cu is being studied in the skin & hair category. Copper tripeptide studied for hair follicle stimulation and scalp health. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is AHK-Cu?
AHK-Cu is a skin & hair peptide. Copper tripeptide studied for hair follicle stimulation and scalp health.
What is AHK-Cu studied for?
Published research has examined AHK-Cu for hair follicle support, scalp microcirculation, anagen phase research. Human clinical evidence varies by indication.
Is AHK-Cu FDA-approved?
No. AHK-Cu is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is AHK-Cu used in research?
Protocols vary by study. AHK-Cu is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for AHK-Cu is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.